Literature DB >> 29311733

Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.

Donata Lissner1, Rainer Glauben1, Kristina Allers1, Elena Sonnenberg1, Christoph Loddenkemper2, Thomas Schneider1, Britta Siegmund1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29311733     DOI： 10.1038/ajg.2017.395

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  6 in total

1.  Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies.

Authors:  P Bonniere; B Wallaert; A Cortot; X Marchandise; Y Riou; A B Tonnel; J F Colombel; C Voisin; J C Paris
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

Review 2.  Pulmonary diseases associated with inflammatory bowel diseases.

Authors:  Giovanni Casella; Vincenzo Villanacci; Camillo Di Bella; Elisabetta Antonelli; Vittorio Baldini; Gabrio Bassotti
Journal:  J Crohns Colitis       Date:  2010-03-17       Impact factor: 9.071

Review 3.  Integrins: therapeutic targets in airway hyperresponsiveness and remodelling?

Authors:  David B Wright; Herman Meurs; Bart G J Dekkers
Journal:  Trends Pharmacol Sci       Date:  2014-10-16       Impact factor: 14.819

4.  The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.

Authors:  Sebastian Zundler; Anika Fischer; Daniela Schillinger; Marie-Theres Binder; Raja Atreya; Timo Rath; Rocío Lopez-Pósadas; Caroline J Voskens; Alastair Watson; Imke Atreya; Clemens Neufert; Markus F Neurath
Journal:  Inflamm Bowel Dis       Date:  2017-03       Impact factor: 5.325

5.  Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.

Authors:  D C Baumgart; B Bokemeyer; A Drabik; A Stallmach; S Schreiber
Journal:  Aliment Pharmacol Ther       Date:  2016-04-01       Impact factor: 8.171

6.  The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Authors:  Jean-Frédéric Colombel; Bruce E Sands; Paul Rutgeerts; William Sandborn; Silvio Danese; Geert D'Haens; Remo Panaccione; Edward V Loftus; Serap Sankoh; Irving Fox; Asit Parikh; Catherine Milch; Brihad Abhyankar; Brian G Feagan
Journal:  Gut       Date:  2016-02-18       Impact factor: 23.059
  6 in total
  6 in total

Review 1.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

2.  Crohn's Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab.

Authors:  Aasem Abu Shtaya; Shai Cohen; Yana Kogan; Michal Shteinberg; Ori Sagool
Journal:  Eur J Case Rep Intern Med       Date:  2021-02-19

3.  Noninfectious Pulmonary Complications Associated With Anti-Integrin Therapy: A Case Report and Systematic Review of the Literature.

Authors:  David Dulaney; Priya Dave; Samantha Walsh; Saurabh Mehandru; Jean-Frederic Colombel; Manasi Agrawal
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

4.  Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report.

Authors:  Jie Zhang; Mei-Hong Liu; Xue Gao; Chang Dong; Yan-Xia Li
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

5.  Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis.

Authors:  Wanwan Zhu; Tianhao Zhao; Jun Wei; Damin Chai; Cancan Zhao; Yu Zhu; Min Deng
Journal:  Front Med (Lausanne)       Date:  2022-08-05

Review 6.  Anti-integrin therapy for inflammatory bowel disease.

Authors:  Sung Chul Park; Yoon Tae Jeen
Journal:  World J Gastroenterol       Date:  2018-05-07       Impact factor: 5.742
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.